Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Century Therapeutics Inc (NQ: IPSC )

1.350 +0.050 (+3.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics Inc

< Previous 1 2 3 4 Next >
Top 5 Health Care Stocks That May Surge
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. 
Via InvestorPlace
8 Analysts Have This to Say About Century Therapeutics
Via Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
Via Benzinga
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
From Century Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
Century Therapeutics to Present at the SITC 37th Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
From Century Therapeutics, Inc.
Via GlobeNewswire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Announced Clearance To Century Therapeutics' Allogeneic Cell Therapy Candidate Study
Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or... 
Via Benzinga
U.S. Stock Futures Higher Following Friday's Rally
Pre-open movers 
Via Benzinga
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K... 
Via Benzinga
45 Stocks Moving In Monday's Mid-Day Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The company's market cap stands at $674.6 million. Apria (... 
Via Benzinga
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to... 
Via Benzinga
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
From Bristol Myers Squibb
Via Business Wire
51 Biggest Movers From Yesterday
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.